CFRX Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (5 Dez 2023 @ 21:31):

Stats
Tagesvolumen	910 216
Durchschnittsvolumen	262 784
Marktkapitalisierung	371 901
EPS	$0 ( 2024-03-29 )
Nächstes Ertragsdatum	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.00462
ATR14	$0.0290 (82.98%)

Insider Trading

Date	Person	Action	Amount	type
2023-02-14	Messinger Michael	Buy	25 000	Options (Right to Buy)
2022-05-17	Barlow Jane F	Buy	42 000	Options (Right to Buy)
2022-05-17	Sucoff Cary	Buy	42 000	Options (Right to Buy)
2022-05-17	Otto Michael J.	Buy	42 000	Options (Right to Buy)
2022-05-17	Low David N.	Buy	42 000	Options (Right to Buy)

INSIDER POWER
100.00
Last 55 transactions
Buy: 2 642 000 \| Sell: 9 700 000

Volumen Korrelation

Lang: -0.02 (neutral)

Kurz: -0.53 (weak negative)

Signal:(32.31) Neutral

ContraFect Corp Korrelation

10 Am meisten positiv korreliert
ENNV	0.961
EVLO	0.96
CLFD	0.952
ALXO	0.951
YJ	0.95
NAKD	0.949
SLNG	0.946
GXGX	0.946
REYN	0.945
BHTG	0.943

10 Am meisten negativ korreliert
TIOAU	-0.973
VLAT	-0.97
LGVC	-0.97
PRLH	-0.967
FICV	-0.966
TIOA	-0.964
SCRM	-0.963
IVCP	-0.962
INTA	-0.962
LDHA	-0.961

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

ContraFect Corp Korrelation - Währung/Rohstoff

0.27
( neutral )

-0.60
( weak negative )

0.00
( neutral )

-0.04
( neutral )

0.58
( weak )

-0.35
( neutral )

ContraFect Corp Finanzdaten

Annual	2022
Umsatz:	$0
Bruttogewinn:	$0 (0.00 %)
EPS:	$-126.01

FY	2022
Umsatz:	$0
Bruttogewinn:	$0 (0.00 %)
EPS:	$-126.01

FY	2021
Umsatz:	$0.00
Bruttogewinn:	$0.00 (0.00 %)
EPS:	$-0.891

FY	2020
Umsatz:	$0.00
Bruttogewinn:	$0.00 (0.00 %)
EPS:	$-1.240

Financial Reports:

No articles found.

ContraFect Corp

ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia. The company also develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis; and CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also initiated an expanded access program to provide Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York.